• Explore /
  • Poster
  • / Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).

Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).

Abstract Poster

Authors

null

Sarah E. R. Halford

Cancer Research UK Centre for Drug Development, London, United Kingdom

Sarah E. R. Halford , Garth Cruickshank , Laurence Dunn , Sara Erridge , Lisa Godfrey , Christopher Herbert , Sarah Jefferies , Juanita Suzanne Lopez , Catherine McBain , Marc Pittman , Rebecca Sleigh , Colin Watts , Mark F Webster-Smith , Anthony J. Chalmers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Brain Metastases

Clinical Trial Registration Number

NCT01390571

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2022)

DOI

10.1200/JCO.2017.35.15_suppl.2022

Abstract #

2022

Poster Bd #

264

Abstract Disclosures

Similar Posters

First Author: Anthony J. Chalmers

First Author: Anthony J. Chalmers

First Author: Lawrence Kleinberg

First Author: Dinu Stefan